Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 6/24/2017 10:24:05 PM - Followers: 145 - Board type: Free - Posts Today: 0

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.





Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.


Current Price
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
#4254  Sticky Note ONCE AGAIN, PRICING PROJECTION by TC... Jesspro 06/02/17 11:59:16 AM
#4517   The difference is AUPH is a blinded trial biotech_researcher 06/24/17 10:24:05 PM
#4516   $80. Vid:"Duggan would be to Aurinia what Denner grandma_of_jbraika 06/24/17 12:20:12 PM
#4515   Pretty nice day today.. It does have a biotech_researcher 06/23/17 11:24:24 PM
#4512   vidpok45: "...80 per share ..." Ronald: "... hope grandma_of_jbraika 06/23/17 06:46:49 AM
#4510   May be we have a better day tomorrow.... biotech_researcher 06/22/17 08:42:09 PM
#4509   37<80. Vid:"80 per share ... in light of grandma_of_jbraika 06/22/17 04:38:24 AM
#4508   Meeting was upbeat. Here is the link wJulie 06/21/17 02:24:08 PM
#4504   Well, did Glickman say if this cash can Jesspro 06/21/17 02:14:44 PM
#4503   the meeting was short and not very informative, thesaud 06/21/17 01:41:56 PM
#4502   since you sold at 6.00 this should not cervelo 06/21/17 12:54:48 PM
#4501   Wow, getting crushed again down biotech_researcher 06/21/17 12:19:34 PM
#4500   "AUPH is ripe for a squeeze!" I moosedogger 06/21/17 10:17:03 AM
#4499   Smell the fear! WOw, shorts desperate to the gipper 06/21/17 09:42:18 AM
#4498   webcast today at shareholder meeting that's pacific time thesaud 06/21/17 07:39:04 AM
#4497   Thanks, Lunacy and Jess. A.F. says AUPH is grandma_of_jbraika 06/21/17 07:17:09 AM
#4495 https://www.nytime Lunacy aka John Galt 06/20/17 10:09:15 PM
#4493   I think biotech in general is up today Maciste 06/20/17 02:50:16 PM
#4492   Sure acting like some significant news may be the gipper 06/20/17 02:20:48 PM
#4491   the ibb is looking strong ready for up thesaud 06/20/17 12:09:38 PM
#4490   Nice move today. Need staying power now.. biotech_researcher 06/20/17 11:51:47 AM
#4487   $80>$37. "We have bottomed at around 6. May grandma_of_jbraika 06/20/17 06:41:19 AM
#4485   Been to heck and back with Ariad, lost Merc1 06/19/17 08:51:27 PM
#4479   we cannot even get to 2M shares on althegambler 06/19/17 03:09:35 PM
#4478   Afternoon fade.. I thought this morning would be biotech_researcher 06/19/17 02:42:42 PM
#4477   looking at the trading going on and lack althegambler 06/19/17 02:18:39 PM
#4474 remmy222 06/19/17 08:36:01 AM
#4472   Lol...hope all Fathers had a great day! SvsB 06/18/17 09:49:20 PM
#4471   Should be a good day tomorrow.. biotech_researcher 06/18/17 08:52:04 PM
#4470   Happy Father's Day. You can delete Maciste 06/18/17 12:15:48 PM
#4469   Vid: "A buyout for 2x revenue would yield grandma_of_jbraika 06/18/17 01:36:40 AM
#4460  Restored Wow, no help... Why??? biotech_researcher 06/16/17 04:49:27 PM
#4455   Cervelo -- I think you would agree that SantaFe Miguel 06/16/17 02:06:26 PM
#4453   2x duration in remission compared to control is Awlau 06/16/17 08:52:14 AM
#4452 remmy222 06/16/17 08:40:33 AM
#4451   Start your engines!!!! remmy222 06/16/17 08:17:30 AM
#4450   ILJIN has been being absolutely the #1 AUPH grandma_of_jbraika 06/16/17 06:07:31 AM
#4448   vidpok45: "80 per share seems very possible in grandma_of_jbraika 06/16/17 05:52:20 AM
#4447   No apologies necessary- to the contrary, it's good moosedogger 06/15/17 05:02:40 PM
#4446   Thanks for the info. That's sort of what Awlau 06/15/17 03:22:29 PM
#4445   "AUPH wasn't even in existence in 2007." moosedogger 06/15/17 03:12:18 PM
#4444   CNBC app shows the prices and the dates biotech_researcher 06/15/17 03:09:32 PM
#4441   AUPH wasn't even in existence in 2007. Awlau 06/15/17 01:24:00 PM
#4439   Wow, that is pretty deeeeepppp. I wish Maciste 06/15/17 12:19:46 PM
#4437   Yes I was lucky to have found ARIA SvsB 06/15/17 11:10:02 AM
#4435   $37, not $80 was his estimate. Foxxycleopatra 06/15/17 08:37:15 AM
#4432   Vid is holding long and strong, just no Lunacy aka John Galt 06/15/17 07:52:19 AM
#4429   Hilarious! Love the biting wit. moosedogger 06/15/17 07:08:37 AM
#4426   Just curious how many shares you guys are JWard99 06/15/17 04:58:14 AM
#4424   Yes what a bummer. It was also a SvsB 06/14/17 11:00:10 PM
#4423   "If it falls below $6, I liquidate all". SantaFe Miguel 06/14/17 10:35:04 PM